Rvnc investors have opportunity to lead revance therapeutics, inc. securities fraud lawsuit

Los angeles, jan. 27, 2022 /prnewswire/ -- glancy prongay & murray llp ("gpm") announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against revance therapeutics, inc. ("revance" or the "company") (nasdaq: rvnc). class period: november 25, 2019 – october 11, 2021 lead plaintiff deadline: february 8, 2022 if you wish to serve as lead plaintiff of the revance lawsuit, you can submit your contact information at www.glancylaw.com/cases/revance-therapeutics-inc/.
RVNC Ratings Summary
RVNC Quant Ranking